HOME >> BIOLOGY >> NEWS
Early environmental exposure may accelerate age-related neurodegeneration

WASHINGTON, DC June 27, 2007 -- Exposure to iron during the first weeks of life in combination with exposure later in life to a common herbicide may contribute to the subsequent degeneration of brain cells associated with the onset of Parkinsons disease (PD), according to a new study in mice. The findings also showed that a compound that protects cells in the body from damage from certain forms of oxygen, a kind of antioxidant, could suppress such neural degeneration.

Previous studies indicated that both early exposure to iron and later exposure to the herbicide paraquat independently increase oxidative stressan environment in which damage from levels of reactive oxygen is more likelyin dopamine-producing regions of the brain, areas that are affected by PD. Julie Andersen, PhD, and her team at the Buck Institute for Age Research found that feeding iron to newborn mice made them more susceptible to paraquat, which increases levels of harmful forms of oxygen and damages dopamine-producing neurons as they grew older. The study appears in the June 27 issue of The Journal of Neuroscience.

The importance of the study is that it points to a possible role of common mechanisms triggered by iron and paraquat as important in PD, and suggests that therapies that block their effects would be worth testing in patients, says Marie-Francoise Chesselet, MD, PhD, of UCLA, who did not participate in the study.

Ten-day-old mice were fed iron for a week. At ages from two months to two years, they were then exposed to paraquat for three weeks. By examining their brains, Andersen and her team found that by the time the mice were a year old, early iron consumption exacerbated damage to brain cells caused by paraquat exposure. The effect was even more pronounced at two years of age, the human equivalent of 6070 years.

A subset of mice that received the antioxidant at the same time that they were exposed to paraquat exhibited reduced leve
'"/>

Contact: Sara Harris
sharris@sfn.org
202-962-4000
Society for Neuroscience
27-Jun-2007


Page: 1 2

Related biology news :

1. Early fire risk for mountains near Los Angeles
2. Early exposure to indoor fungus molecules may protect infants against future allergies
3. Early-stage sperm cells created from human bone marrow
4. Early Europeans unable to stomach milk
5. Early HIV treatment fails to restore memory T cells
6. Early Earth haze may have spurred life, says University of Colorado study
7. Early detection
8. Early family experience can reverse the effects of genes, UCLA psychologists report
9. Early to bed, early to rise
10. Early exposure to synthetic estrogen puts DES Daughters at higher risk for breast cancer
11. Top researcher-educators receive Presidential Early Career Award for Scientists and Engineers

Post Your Comments:
(Date:7/23/2015)... 2015 Aware, Inc. (NASDAQ: AWRE ), a ... results for its second quarter ended June 30, 2015.  ... $4.5 million, a decrease of 33% compared to $6.8 million ... second quarter of 2015 was $0.3 million, or $0.01 per ... diluted share, in the same period a year ago.  ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
(Date:7/30/2015)... (PRWEB) , ... July 31, 2015 , ... Ralco is ... Center at the Lyon County Fair to be held August 5-9 in Marshall. The ... where their meals come from and how agriculture impacts their daily lives. This unique ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: